🔗 Permalink

Inventor profile of:

Martin E. Gleave

City:

Vancouver

Country:

Canada

Published Applications:

Last publication date:

2025-06-26

Top Assignees for applications by Martin E. Gleave

The entities that hold a legal rights for patent applications filed by inventor Gleave Martin E.:

The University of British Columbia 34 Vancouver, Canada
The University of British Columbia 6 Vancouver, BC Canada
Centre for Drug Research and Development 4 Vancouver, Canada
Centre for Drug Research and Development 1 Vancouver, BC Canada
THE UNIVERSITY OF BRITISH COLUMBIA 1 Vancouver, British Columbia, Canada

Recent patent applications by Gleave Martin E.

Martin E. Gleave from Vancouver, CA has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-26

US20250205340A1

Human necessities

Mucoadhesive Polymeric Drug Delivery Compositions and Methods

#2 | 2023-02-09

US20230042600A1

Human necessities

Mucoadhesive polymeric drug delivery compositions and methods

#3 | 2022-05-19

US20220152207A1

Human necessities

Polymeric Paste Compositions for Drug Delivery

#4 | 2022-02-17

US20220048973A1

Chemistry; metallurgy

B1SP Fusion Protein Therapeutics, Methods, and Uses

#5 | 2020-05-14

US20200147223A1

Human necessities

Polymeric paste compositions for drug delivery

#6 | 2019-07-04

US20190201528A1

Human necessities

Derivatized hyperbranched polyglycerols

#7 | 2018-06-14

US20180162923A1

Chemistry; metallurgy

B1SP fusion protein therapeutics, methods, and uses

#8 | 2017-11-09

US20170319696A1

Human necessities

Derivatized hyperbranched polyglycerols

#9 | 2017-05-25

US20170145418A1

Chemistry; metallurgy

Combination of Anti-Clusterin Oligonucleotide with HSP90 Inhibitor for the Treatment of Prostate Cancer

#10 | 2017-01-19

US20170015997A1

Chemistry; metallurgy

Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer

#11 | 2016-11-10

US20160326527A1

Chemistry; metallurgy

Compositions and methods for treatment of prostate and other cancers

#12 | 2016-06-16

US20160168577A1

Chemistry; metallurgy

Clusterin Antisense Therapy for Treatment of Cancer

#13 | 2016-04-28

US20160114040A1

Human necessities

Derivatized hyperbranched polyglycerols

#14 | 2016-01-07

US20160002630A1

Chemistry; metallurgy

Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

#15 | 2015-08-20

US20150232843A1

Chemistry; metallurgy

Compositions and methods for treatment of prostate and other cancers

#16 | 2015-06-11

US20150157656A1

Human necessities

Method for treatment of castration-resistant prostate cancer

#17 | 2015-02-19

US20150050285A1

Human necessities

Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates

#18 | 2015-01-08

US20150010561A1

Chemistry; metallurgy

Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses

#19 | 2014-10-23

US20140315978A1

Chemistry; metallurgy

Compositions and methods for treatment of prostate and other cancers

#20 | 2014-08-28

US20140242192A1

Chemistry; metallurgy

Clusterin antisense therapy for treatment of cancer

#21 | 2014-03-27

US20140088178A1

Human necessities

COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH ANDROGEN RECEPTOR ANTAGONIST FOR THE TREATMENT OF PROSTATE CANCER

#22 | 2014-03-20

US20140080895A1

Human necessities

Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer

#23 | 2013-11-14

US20130303592A1

Human necessities

Treatment of cancer by inhibition of IGFBPs and clusterin

#24 | 2013-06-13

US20130150429A1

Physics

P27KIP1 AS A MOLECULAR MARKER FOR SUITABILITY AND EFFICACY OF TREATMENT WITH HSP27 INHIBITORS

#25 | 2013-05-16

US20130122112A1

Human necessities

Derivatized hyperbranched polyglycerols

#26 | 2013-01-31

US20130028896A1

Chemistry; metallurgy

Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses

#27 | 2012-08-30

US20120220646A1

Chemistry; metallurgy

Treatment of cancer by inhibition of IGFBPs and clusterin

#28 | 2012-08-28

US10646436

RNAi probes targeting cancer-related proteins

#29 | 2011-08-11

US20110196019A1

Chemistry; metallurgy

Treatment of cancer by inhibition of IGFBPs and clusterin

#30 | 2011-08-04

US20110190382A1

Chemistry; metallurgy

Treatment of cancer by inhibition of IGFBPs and clusterin

#31 | 2011-06-23

US20110152354A1

Chemistry; metallurgy

Bispecific oligonucleotide for the treatment of CNS malignancies

#32 | 2009-11-26

US20090292008A1

Human necessities

Compositions and methods for treatment of prostate and other cancers

#33 | 2009-09-03

US20090221678A1

Chemistry; metallurgy

Compositions and methods for treatment of prostate and other cancers

#34 | 2008-10-23

US20080261912A1

Chemistry; metallurgy

Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same

#35 | 2008-05-22

US20080119425A1

Chemistry; metallurgy

Clusterin antisense therapy for treatment of cancer

#36 | 2006-09-05

US10605498

Compositions and methods for treatment of prostate and other cancers

#37 | 2006-08-10

US20060178329A1

Chemistry; metallurgy

RNAi probes targeting cancer-related proteins

#38 | 2006-06-08

US20060122141A1

Chemistry; metallurgy

Treatment of cancer by inhibition of IGFBP's and clusterin

#39 | 2006-02-23

US20060040886A1

Chemistry; metallurgy

Compositions and methods for treatment of prostate and other cancers

#40 | 2006-01-12

US20060009405A1

Chemistry; metallurgy

Bispecific oligonucleotide for the treatment of CNS malignancies

InventorID:

65843 ⎘